Bioiberica recognized for innovation

The global life science company Bioiberica has received Frost & Sullivan’s 2025 European New Product Innovation Recognition in the innovative collagen solutions industry for its achievements in clinical validation, ingredient differentiation, and evidence-based product development.

Frost & Sullivan evaluates companies through a benchmarking process across two core-dimensions: strategy effectiveness and execution. According to a press release, Bioiberica excelled in both by aligning long-term scientific strategy with market demand while executing with precision, consistency, and regulatory discipline.

The recognized product is Collavant N2, a native type II collagen ingredient derived from chicken sternum cartilage. It preserves the collagen’s molecular structure and delivers efficacy at a low daily dose of 40 milligrams through an immune-mediated mechanism of action. Unlike denatured collagen peptides that rely on gram-level dosing, Collavant N2 offers a differentiated formulation strategy supported by randomized, controlled clinical trials demonstrating support in joint comfort, mobility, and functional performance.

‘Bioiberica distinguishes Collavant N2 by providing mechanistic clarity and efficacy both in terms of joint comfort and potential cartilage preservation, setting it apart in a market that often lacks transparent clinical substantiation,’ commented Sreedevi Kakkad, Senior Research Analyst, TechVision at Frost & Sullivan.